Data To Be Presented At Highlighting GENFIT???s Latest Progress In NASH Biomarker Diagnostics, Identifying Novel Compounds With Potent Antifibrotic Properties, And Illustrating The Opportunities In Anti-NASH Drug Combinations Post author:Sam Post published:April 4, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like FDA's Shorten Review Time is a Bad Sign for Puma Biotech's Controversial Cancer Drug April 18, 2017 Enumeral Biomedical Gets Evicted as it Winds Down Operations August 28, 2017 AbbVie’s Elagolix Hits Primary Endpoints for Uterine Fibroids February 20, 2018